Utility of flow cytometry screening before MRD testing in multiple myeloma

Blood Cancer J. 2023 Apr 20;13(1):55. doi: 10.1038/s41408-023-00832-8.

Authors

Vandana Panakkal¹, Arjun Lakshman^{1

2}, Min Shi³, Horatiu Olteanu³, Pedro Horna³, Michael M Timm³, Gregory E Otteson³, Linda B Baughn^{3

4}, Patricia T Greipp^{3

4}, Wilson I Gonsalves¹, Prashant Kapoor¹, Morie A Gertz¹, Moritz Binder¹, Francis K Buadi¹, Angela Dispenzieri¹, S Vincent Rajkumar¹, Shaji K Kumar¹, Dragan Jevremovic⁵

Affiliations

¹ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
² Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
³ Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.
⁴ Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
⁵ Division of Hematopathology, Mayo Clinic, Rochester, MN, USA. Jevremovic.Dragan@mayo.edu.

No abstract available

Publication types

Letter

MeSH terms

Flow Cytometry
Humans
Multiple Myeloma* / diagnosis
Neoplasm, Residual / diagnosis

Grants and funding

R01 CA168762/CA/NCI NIH HHS/United States